The glycemic, cholesterol, and weight effects of L-carnitine in diabetes: A systematic review and meta-analysis of randomized controlled trials

IF 1 Q4 ENDOCRINOLOGY & METABOLISM Diabetes epidemiology and management Pub Date : 2023-04-01 DOI:10.1016/j.deman.2022.100122
Jennifer Ko , Eva Y. Wong , Huyentran N. Tran , Rebecca J.C. Tran , Diana X. Cao
{"title":"The glycemic, cholesterol, and weight effects of L-carnitine in diabetes: A systematic review and meta-analysis of randomized controlled trials","authors":"Jennifer Ko ,&nbsp;Eva Y. Wong ,&nbsp;Huyentran N. Tran ,&nbsp;Rebecca J.C. Tran ,&nbsp;Diana X. Cao","doi":"10.1016/j.deman.2022.100122","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>L-carnitine possibly impacts insulin sensitivity and glucose metabolism. However, its therapeutic role in diabetes is poorly understood.</p></div><div><h3>Methods</h3><p>A systematic review and meta-analysis were conducted using PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception through June 30, 2021. Included studies evaluated the use of L-carnitine in diabetes on fasting blood glucose (FBG), hemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), weight, or body mass index (BMI). Weighted mean difference (WMD) and 95% confidence intervals (CI) were calculated using the DerSimonian and Laird random-effects model.</p></div><div><h3>Results</h3><p>Seventeen studies involving 1622 patients were included. Reductions in FBG (WMD = -0.46 mmol/L, 95% CI = -0.68 to -0.23 mmol/L), HbA1c (WMD = -0.5%, 95% CI = -0.8 to -0.1%), TC (WMD = -0.29 mmol/L, 95% CI = -0.42 to -0.16 mmol/L), and LDL-C (WMD = -0.23 mmol/L, 95% CI = -0.39 to -0.07 mmol/L) were significant. Effects on HDL-C, TG, weight, or BMI were insignificant. Doses between 1001 to 2000 mg showed greatest benefit (<em>p</em> &lt; 0.02 for all).</p></div><div><h3>Discussion/Conclusion</h3><p>L-carnitine plays a potential role as adjunctive therapy in diabetes. Additional research is necessary for patients with higher baseline HbA1c and type 1 diabetes.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"10 ","pages":"Article 100122"},"PeriodicalIF":1.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes epidemiology and management","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666970622000725","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

L-carnitine possibly impacts insulin sensitivity and glucose metabolism. However, its therapeutic role in diabetes is poorly understood.

Methods

A systematic review and meta-analysis were conducted using PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception through June 30, 2021. Included studies evaluated the use of L-carnitine in diabetes on fasting blood glucose (FBG), hemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), weight, or body mass index (BMI). Weighted mean difference (WMD) and 95% confidence intervals (CI) were calculated using the DerSimonian and Laird random-effects model.

Results

Seventeen studies involving 1622 patients were included. Reductions in FBG (WMD = -0.46 mmol/L, 95% CI = -0.68 to -0.23 mmol/L), HbA1c (WMD = -0.5%, 95% CI = -0.8 to -0.1%), TC (WMD = -0.29 mmol/L, 95% CI = -0.42 to -0.16 mmol/L), and LDL-C (WMD = -0.23 mmol/L, 95% CI = -0.39 to -0.07 mmol/L) were significant. Effects on HDL-C, TG, weight, or BMI were insignificant. Doses between 1001 to 2000 mg showed greatest benefit (p < 0.02 for all).

Discussion/Conclusion

L-carnitine plays a potential role as adjunctive therapy in diabetes. Additional research is necessary for patients with higher baseline HbA1c and type 1 diabetes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
左旋肉碱对糖尿病的血糖、胆固醇和体重影响:随机对照试验的系统回顾和荟萃分析
左旋肉碱可能影响胰岛素敏感性和葡萄糖代谢。然而,其在糖尿病中的治疗作用尚不清楚。方法从研究开始到2021年6月30日,使用PubMed、EMBASE和Cochrane中央对照试验登记册(Central)进行系统评价和荟萃分析。纳入的研究评估了在糖尿病患者中使用左旋肉碱对空腹血糖(FBG)、血红蛋白A1c (HbA1c)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、体重或体重指数(BMI)的影响。加权平均差(WMD)和95%置信区间(CI)采用DerSimonian和Laird随机效应模型计算。结果纳入17项研究,共1622例患者。减少光纤光栅(大规模杀伤性武器= -0.46更易与L, 95% CI = -0.68到-0.23更易/ L),糖化血红蛋白(大规模杀伤性武器= -0.5%,95% CI = -0.8到-0.1%),TC(大规模杀伤性武器= -0.29更易与L, 95% CI = -0.42到-0.16更易/ L),和低密度(大规模杀伤性武器= -0.23更易与L, 95% CI = -0.39到-0.07更易/ L)是重要的。对HDL-C、TG、体重或BMI的影响不显著。剂量在1001至2000毫克之间显示出最大的益处(p <所有人都是0.02)。讨论/结论左旋肉碱在糖尿病的辅助治疗中具有潜在的作用。对于基线HbA1c较高和1型糖尿病患者,有必要进行进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes epidemiology and management
Diabetes epidemiology and management Endocrinology, Diabetes and Metabolism, Public Health and Health Policy
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
14 days
期刊最新文献
Innovative immunotherapies and emerging treatments in type 1 diabetes management Autoantibodies in type 1 diabetes: Prevalence and clinical profiles Reply to increase in diabetic deaths during COVID-19 pandemic. Some comments High prevalence of prediabetes and type 2 diabetes, and identification of associated factors, in high-risk adults in Vietnam: A cross-sectional study editorial board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1